Biotech hopeful Amplia Therapeutics has been given the green light to begin its “ACCENT-Mini” clinical trial after receiving ethics approval to test its lead drug candidate, narmafotinib, alongside chemotherapy in patients with metastatic pancreatic cancer.
The approval is a critical milestone, allowing the company to start recruiting patients across three selected Australian clinical trial sites, where start-up activities are already well advanced. The ACCENT-Mini trial will evaluate a daily-dosed regimen of narmafotinib to determine the optimal safe and effective dosing rate.
The new trial builds on encouraging data from Amplia’s previous…
Read the full article at SMH.COM.AU











